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Proteomic investigations of sera are potentially of value 
for diagnosis, prognosis, choice of therapy, and disease 
activity assessment by virtue of discovering new biomar­
kers and biomarker patterns. Much debate focuses on the 
biological relevance and the need for identification of such 
biomarkers while less effort has been invested in devising 
standard procedures for sample preparation and storage 
in relation to model building based on complex sets of 
mass spectrometric (MS) data. Thus, development of 
standardized methods for collection and storage of patient 
samples together with standards for transportation and 
handling of samples are needed. This requires knowledge 
about how sample processing affects MS-based proteome 
analyses and thereby how nonbiological biased classifica­
tion errors are avoided. In this study, we characterize the 
effects of sample handling, including clotting conditions, 
storage temperature, storage time, and freeze/thaw cycles, 
on MS-based proteomics of human serum by using 
principal components analysis, support vector machine 
learning, and clustering methods based on genetic algo­
rithms as class modeling and prediction methods. Using 
spiking to artificially create differentiable sample groups, 
this integrated approach yields data that—even when 
working with sample groups that differ more than may be 
expected in biological studies—clearly demonstrate the 
need for comparable sampling conditions for samples 
used for modeling and for the samples that are going into 
the test set group. Also, the study emphasizes the differ­
ence between class prediction and class comparison 
studies as well as the advantages and disadvantages of 
different modeling methods.
In recent years, mass spectrometry (MS) has become the 
mainstay of efforts to exploit biofluid proteomic patterns for the 
discovery of novel biomarkers for diagnosis, prognosis, choice of 
therapy, and disease activity assessment, especially in the field 
of cancer.1-2 Compared with the only other high-resolution method
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forbiofluid proteome analysis—two-dimensionalgel electrophoresis— 
MS has the obvious virtues of providing a digitized output, 
requiring less material, being easily automated, being less labor 
intensive, having higher throughput capabilities, and being capable 
of analyzing the peptide population below 5000-10 000 molecular 
weight. Also, molecular identification is, in principle, integral to 
the approach. Used on adequate patient and control materials and 
combined with proper data mining methods, quite large mass-to- 
charge intensity data sets may be readily pruned for peak patterns 
specific and predictive for disease. Accordingly, a number of 
publications reporting MS proteomic analysis-based biomarker 
discoveries in bladder, prostate, breast, and lung cancer in addition 
to ovarian cancer have now appeared.3-11
Concurrently, concerns have been voiced about the validity of 
the approach. This is mainly due to nonreproducible results and 
less obvious biological correlates of findings. One problem is, for 
example, that very low molecular weight (below 500) candidate 
biomarkers are reported in several studies.4-12 Such components 
may originate from experimental bias and noise effects without 
biological provenience even though they appear to facilitate model 
discrimination between patients and normal.13-17 Furthermore,
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analyses of the same sample sets in independent laboratories have 
revealed nonreproducible discriminatory patterns.2 Differences in 
instruments, in data acquisition methods, and in data transforma­
tion and data mining software may account for many discrepan­
cies, but the lack of standardization and the lack of systematic 
studies of the influence of sample handling and sample treatment 
on MS-based proteomic data probably also contribute significantly 
to these discrepancies. The performance of data mining methods 
on more or less deteriorated samples has not been examined 
systematically. Several initiatives are currently being undertaken 
to deal with sampling issues and with controversies of proteomic 
pattern recognition and biomarker discovery.11,16,18-23 To investi­
gate the stability of serum and plasma samples in relation to 
diagnostically valid, mass spectrometry-based proteomic clas­
sification models, we here address the issues of sampling and 
sample handling and the robustness of modeling as a function of 
sample state for human serum and plasma. The approach focuses 
on analytes below 10 000 molecular weight using sample extrac­
tion with C8-derivatized magnetic beads and standard MALDI- 
TOF MS. Data analysis was carried out using principal compo­
nents analysis (PCA), support vector machines (SVMs), and 
clustering based on genetic algorithms. The parameters of clotting 
and handling and storage time, storage temperature, and number 
of freeze/thaw cycles were evaluated in unmodified samples and 
in paired sets of nonspiked and spiked samples to evaluate the 
capabilities of the integrated approach for group classification.
EXPERIMENTAL PROCEDURES
Materials. Purification kit MB-HIC 8 and matrix a-cyano-4- 
hydroxycinnamic acid were purchased from Bruker Daltonik 
GmbH (Leipzig, Germany). Calibration standards containing seven 
peptides and four proteins were used as artificial markers (Bruker 
Daltonik) and consisted of the following molecules with average 
molecular masses (z = 1) given in parentheses: angiotensin II 
(1047.20), angiotensin I (1297.51), substance P (1348.66), bomb­
esin (1620.88), ACTH clip 1-17 (2094.46), ACTH clip 18-39 
(2466.73), somatostatin 28 (3149.61), insulin (5734.56), ubiquitin
I (8565.89), and (with z = 2) cytochrome c (6181.05) and 
myoglobin (8476.77). Ethanol, HPLC grade water, acetonitrile, and 
acetone (Lichrosolv grade) were purchased from Merck.
Biological Samples. Clotting time experiments were con­
ducted with samples from two healthy individuals. The freshly 
drawn blood samples were divided and left to clot for 2, 4, 8, and 
24 h at 4 and 24 °C, respectively, before serum was separated by 
centrifugation at 3000g for 6 min at room temperature. We also 
analyzed eight sera from a 4-year-old sample set (prepared by
(13) Sorace, J. M.; Zhan, M. Bioinformatics 2003, 4, 24.
(14) Baggerly, K. A.; Morris, J. S.; Coombes, K. R. Bioinformatics 2004, 20, 
777-85.
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(16) White, C. N.; Chan, D. W.; Zhang, Z. Clin. Biochem. 2004, 37, 636-41.
(17) Diamandis, E. P. Clin. Chem. 2003, 49, 1272-5.
(18) Cordingley, H. C.; Roberts, S. L.; Tooke, P.; Armitage, J. R.; Lane, P. W.; 
Wu, W.; Wildsmith, S. E. Biotechniques 2003, 34, 364-73.
(19) Petricoin, E., III; Liotta, L. A. Clin. Chem. 2003, 49, 1276-8.
(20) Hulmes, J. D.; Bethea, D.; Ho, K.; Huang, S.; Ricci, D. L.; Opiteck, G. J.; 
Hefta, S. A. Clin. Proteomics 20 04 ,1 , 17-32.
(21) Pusch, W.; Flocco, M. T.; Leung, S. M.; Thiele, H.; Kostrzewa, M. 
Pharmacogenomics. 20 03, 4, 463-76.
(22) Villanueva, J.; Tempst, P. Nature 2004, 430, 611.
(23) Diamandis, E. P. J. Natl. Cancer Inst. 2004, 96, 353-6.
centrifugation at 2000g, 10 min at room temperature), stored at 
-20 °C. These samples were from a study designed to investigate 
the stability of future biochemical markers in relation to clotting 
time and temperature.24-26
For the freeze/thaw experiments, sera from blood samples of 
three healthy volunteers were divided into two identical sample 
sets. One set was stored at -20 °C, and the other set was stored 
at -80 °C.
The temperature and storage time experiments were per­
formed on fresh blood samples from eight healthy volunteers (five 
men, three women, age range 26-55). Paired serum and plasma 
samples were obtained. For serum, the blood was left to clot in 
standard blood collection tubes for 2 h at room temperature. 
Serum was then separated by centrifugation at 3000g for 6 min at 
room temperature. For plasma, the blood was collected in 5-mL 
tubes containing 100 yL of 0.45 mM EDTA and left for 2 h at 
room temperature. The plasma was then isolated by centrifugation 
at 3000g  for 6 min at room temperature. Serum and plasma 
samples from the individual volunteers were divided into two equal 
fractions of 400 yL. One fraction of serum and of plasma was 
spiked with 20 yL (4 pmol/yL) peptide calibration standard and
4 yL (10 pmol/yL) protein calibration standard, i.e., a total of 11 
markers. The control fraction was left unspiked. The spiked and 
nonspiked fractions were subsequently further divided into two 
equal (200 yL) fractions that were left at 4 and 24 °C, respectively, 
with collection of aliquots (5 yL) for MALDI-TOF MS analysis at
0, 1, 4, 8, 24, and, 48 h. (See also Figure 3).
Sample Preparation for Mass Spectrometry. Paramagnetic 
nonporous C8 particles, 0.8 ym in diameter, (MB-HIC 8, Bruker 
Daltonics, Bremen, Germany) were used for preparing subfrac­
tions of serum and plasma samples as outlined by the manufac­
turer. All operations were performed at room temperature. Briefly, 
10 yL of MB-HIC binding solution and 5 yL of serum or plasma 
were transferred to a 0.2-mL thin-walled PCR tube (ABgene). A 
5-yL aliquot of a homogeneous magnetic particle solution was 
added, mixed, and left for 1 min. The tubes were placed in a 2 x 
8 well magnetic bead separator (MBS) (Bruker Daltonik) for 30 
s for magnetic fixation of the MB-HIC 8 particles. The supernatant 
was aspirated, the tubes were removed from the MBS device, and 
100 yL of wash solution was added and carefully mixed with the 
magnetic beads. The tube was then moved back and forth 
sequentially between adjacent wells on each side of the magnetic 
bar in the MBS device. This enhances washing of the magnetic 
particles as they are fixed to the tube wall and then move through 
the washing solution in succession. The sequential washing was 
done 20 times. After fixation of the magnetic beads for 30 s in the 
MBS device, the supernatant was aspirated. The entire washing 
procedure was repeated 3 times. After the final washing step, 
bound molecules were eluted by incubation with 10 yL of 
acetonitrile (50%) for 1 min before collecting the elution solution 
using the MBS device. One microliter of the eluent was mixed 
with 10 yL of matrix solution (0.5 g/L a-cyano-4-hydroxycinnamic 
acid in ethanol/acetone 2:1). One microliter was spotted onto a
(24) Hogdall, E. V.; Johansen, J. S.; Kjaer, S. K.; Price, P. A.; Blaakjaer, J.; Hogdall, 
C. K. Scand. J. Clin. Lab. Invest. 20 00, 60, 247-51.
(25) Hogdall, E. V.; Hogdall, C. K.; Kjaer, S. K.; Xu, F.; Yu, Y.; Bast, R. C.; 
Blaakaer, J.; Jacobs, I. J. Clin. Chem. 1999, 45, 692-4.
(26) Riisbro, R.; Christensen, I. J.; Hogdall, C.; Brunner, N.; Hogdall, E. Int. J. 
Biol. Markers 2001, 16, 233-9.
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600-um-diameter spot size 384 AnchorChip target plate (Bruker 
Daltonik) and left to dry. The peptide and protein calibration 
standard (0.5 ¡uL) in the same matrix was applied to target spots 
in proximity to the serum samples for external calibration of the 
instrument.
During the study, an automated sampling handling robot 
(ClinProt robot, Bruker Daltonik) became available. The work flow 
conducted by the robot is similar to the work flow performed 
manually.
Mass Spectrometry. For all MS experiments, an UltraFlex 
MALDI-TOF mass spectrometer (Bruker Daltonik) controlled by 
FlexControl software v. 2.0 (Bruker Daltonik) was used. The 
instrument is equipped with a 337-nm nitrogen laser, delayed- 
extraction electronics, and a 2-GHz digitizer. The instrument was 
initially externally calibrated by standard procedures. All acqui- 
tions were generated by an automated acquisition method 
included in the instrument software and based on averaging 150 
randomized shots over 5 positions (30 shots/acquisition cycle). 
The acquisition laser power was set between 32 and 36%. Before 
each acquisition cycle, the target area was pretreated with 10 laser 
shots at 45% laser power to improve spectra quality.11 Spectra were 
acquired in positive linear mode geometry under 20 kV of ion 
acceleration, and with ion selector deflection of mass ions of >900 
m /z  in the mass range 925-15 180 Da. This is the analyzed mass 
range throughout the study. Pulsed ion extraction was set to 320 
ns to ensure appropriate time lag focusing. Data acquisition was 
automated through FlexControl using acceptance parameters as 
follows: peak resolution threshold >200 and S/N ratio equal to 
or greater than 15 in the m /z  range 2000-6000.
Data Handling. Spectra were converted into ASCII file format 
using the FlexAnalysis software. Data were subsequently ana­
lyzed by using commercially available analysis programs, Clin- 
ProTools v. 1.0 (Bruker Daltonics) and Unscrambler v. 8.05 
(Camo, Oslo, Norway) as well as by linear SVMs (available at, 
e.g.: http://www.kernel-machines.org/software.html). As our 
sample sets have small sizes, we used a leave-one-out cross­
validation (LOOCV) procedure to analyze the performance of the 
techniques. In LOOCV, all spectra but one are used for generating 
a model, which is then applied to the spectrum left out. This 
process is repeated a number of times equal to the size of the 
data. The average error in applying the generated models to the 
left-out spectra provides an almost unbiased estimate of the true 
error of the classification model.27 Accuracy, defined as the 
proportion of correctly classified spectra, is reported, as well as 
specificity and sensitivity, defined as the fraction of true negative 
(normal correctly classified) of the total negative (normal mis- 
classified + normal correctly classified) and the fraction of true 
positive (spiked correctly classified) of the total positive (spiked 
misclassified + spiked correctly classified), respectively.
Predictive Model Building. ClinProTools. Complex protein 
profile comparison, potential biomarker detection, and differential 
model tests were carried out using ClinProTools. This software 
compares large data sets of different classes, builds predictive 
models from spectra profiles based on discriminators found in 
the data, and returns sensitivity and specificity of the model. The 
predictive models are developed on the basis of genetic algorithms 
that search for combinations of biomarkers (i.e., m /z  values) that
(27) Evgeniou, T.; Pontil, M.; Elisseeff, A Machine Learn. 20 04, 55, 71-97. 
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give the best discrimination of the classes under consideration;4
i.e., class prediction is supervised.28 Genetic algorithms are 
stochastic search procedures inspired by the rules of natural 
selection and natural genetics. Two model building techniques 
are available in this program (k-nearest neighbor and centroid 
clustering). Only centroid clustering was used in the present study 
and the Few Nearly Clean Cluster parameter was applied. The 
mass spectra are viewed as points in an N-dimensional space 
(where N is the number of peaks picked), and similarity between 
pairs of profiles is measured by means of Euclidean distances. 
The centroid clustering process is an iterative classification 
technique that uses the distances between the spectra and the 
centroids of already defined clusters. Spectra are assigned to 
clusters independently of their class membership. Every new 
spectrum is classified by considering the cluster with centroid 
nearest to the spectrum and assigning the class label of its 
elements, which occurs more often. The genetic algorithm 
employs four parameters: model size minimum, model size 
maximum (corresponding to the minimum and maximum number 
of biomarkers to be selected), together with mutation rate and 
crossover rate. The model size was set between 5 and 10, with a 
mutation rate of 0.01 and a crossover rate of 0.9. For tuning the 
model building the parameters used for data preparation are S/N 
ratio, minimum relative peak height, baseline correction, and 
normalization. Standard settings were used throughout except for 
the minimum relative peak height, which was empirically set to 
0.2 to minimize nonpeak picking without losing any real peaks.
Principal Components Analysis. PCA, principal component 
regression (PCR), and partial least squares regression (PLS) were 
used for linear analysis of the data. Objectives of PCA are to 
discover or reduce the dimensionality of the data and to identify 
new meaningful underlying variables. PCR consists of PCA 
followed by multiple linear regression applied to the selected 
principal components. PLS finds components that have high 
variance and have high correlation with the class labels (normal 
and spiked) of the training data. PCA transforms a number of 
possibly correlated variables (e.g., m /z  values) into a smaller 
number of uncorrelated variables called principal components. The 
first principal component accounts for as much variability in the 
data as possible, and each succeeding component accounts for 
as much of the remaining variability as possible. The original data 
are described as linear combinations of loadings and scores. The 
loadings can be understood as the weights for each original 
variable when calculating the principal component, and thus, the 
m /z  values can be retrieved. The scores describe the original data 
in a rotated coordinate system. As model building in the Un­
scrambler program takes every data point in the spectra into 
account, we reduced the number of data points by a factor of 4 
resulting in 22 572 m /z  values/spectrum. All spectra were normal­
ized by a range normalization algorithm, which scales the samples 
to a common range, between 0 and + 1.
Support Vector Machines. Linear SVMs29'30 were used as adjunct 
methods to conduct data analysis related to spiked samples. Data
(28) Simon, R.; Radmacher, M. D.; Dobbin, K.; McShane, L. M. J. Natl. Cancer 
Inst. 2003, 95, 14-8.
(29) Vapnik, V. N. Statistical Learning Theory; John Wiley & Sons: New York,
1998.
(30) Cristianini, N.; Shawe-Taylor, J. Support Vector Machines; Cambridge 
Press: New York, 2000.
F igu re  1. PCA-based prediction of spectra from serum left to clot at different temperatures and time. Serum left to clot at room temperature 
is much more subject to changes over time than serum left to clot at 4 °C. One sample was rejected during the automated MS data acquisition.
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F igu re  2. PCA of the different freeze/thaw cycles of sera stored at -2 0  and -8 0  °C. The scores show the locations of the samples along each 
principal component. Outlier data points were excluded as explained in the text.
were normalized and reduced as described above for the 
PCA data handling. Linear SVM constructs a linear classifier 
described by a hyperplane in the m /z  values space. This 
hyperplane separates the two classes in such a way that its mar­
gin is maximized. The margin is the sum of the minimum 
distances of training points of each class from the hyperplane. 
Regularization is used for dealing with nonlinearly separable 
classes, where a parameter C (here set to 10) is used for penal­
izing misclassification. Biomarker detection based on linear 
SVM is performed using recursive feature elimination, (SVM- 
RFE).31 SVM-RFE recursively eliminates chunks of m /z  values 
that are considered less relevant than the remaining m /z  values, 
according to a relevance criterion based on the weights asso­
ciated to m /z  values resulting from the SVM training. We 
terminate this process when 10 m /z  values (i.e., the maximum 
number of m /z  values used in the ClinProTools biomarker 
selection method) are left, thus choosing for a model dimension 
equal to 10.
(31) Guyon, I.; Weston, J.; Barnhill, S.; Vapnik, V Machine Learn. 2002, 46, 
389-422.
RESULTS AND DISCUSSION
Clotting, Temperature, and Handling Time. The influences 
of blood clotting, handling time, and temperature on the charac­
teristics of the MS data sets were assessed by PCA of spectra. 
Two groups appeared from this analysis. Mass spectra from blood 
left to clot for 8 and 24 h at 24 °C were separated by PCA from 
the rest (blood clotted for 2 and 4 h at 24 °C and 2-24 h at 4 °C) 
(data not shown). By PCR on spectra from samples incubated at
2, 4, 8, and 24 h at 24 °C, a linear model (y = 0.98x + 0.16h, r =
0.99) describes the observed data variation with respect to the 
length of clotting time. A full cross-validation (predicted) yields 
similar parameters (y = 0.96x + 0.50h, r = 0.96) showing the 
consistency of the model. When analyzing spectra from samples 
left to clot at 4 °C for any length of time, this model places them 
in the same group as the samples left to clot at 2 and 4 h at 24 °C 
(Figure 1). Thus, the model evaluates all MS profiles at 4 °C as 
belonging to the group of 24 °C samples clotted for a short time. 
No differences in the MS profiles of serum from blood left to clot 
from 2 to 24 h at 4 °C compared with blood left to clot at 2 and 4 
h at 24 °C thus were discernible by PCA (Figure 1). Conversely,
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the samples left to clot for longer times (8-24 h) at 24 °C 
displayed clearly changed m /z  profiles (as the possibility of 
building a clotting time-based linear model from the 24 °C data 
indicates). The results indicate the need to avoid different clotting 
and handling times and temperatures when collecting material 
for clinical proteomics and that less than 4hat24 °C is preferable.
Analysis of archival sera (stored four years at -20 °C) 
representing blood samples from eight women clotting at different 
temperatures (4 °C or room temperature) and for different times 
(1, 3, and 72 h) was initially performed as above, but PCR did not 
yield a linear time dependency as with the fresh samples (data 
not shown). However—using PLS analysis of the mass spectra— 
it could be shown that the only sample group that was differenti­
ated by PCA of m /z  spectra in this sample set was samples left to 
clot for 72 h at room temperature (data not shown). This is in 
agreement with the results above using fresh samples and with 
the original results from Hogdall et al.,24 who only found changes 
in a specific protein marker (YKL-40) in the samples left to clot 
at room temperature for 72 h.
Previous studies have indicated that freeze/thaw cycles have 
no effect on a number of specific protein markers in serum.24-26 
We analyzed three different serum samples divided into two 
groups that were stored at either -20 or -80 °C. The -20 °C 
samples were thawed and frozen 5 times over 5 days, and samples 
kept at -80 °C were thawed and frozen 4 times over 4 days. Data 
analysis of mass spectra by PCA indicated no gross differences 
in the m /z  data distribution in the samples kept at one specific 
temperature and repeatedly sampled daily. Also, it was not possible 
to observe any differences between the samples stored at -20 
and -80 °C, cf. Figure 2. One spectrum (-20 °C, second thaw) 
was not acquired because it was rejected by the resolution and 
S/N settings of the MS data acquisition program. Further, four 
data sets (three from the second freeze/thaw experiment of -80 
°C samples and one -20 °C set from the fourth freeze/thaw 
experiment) became outliers because of an artifactual peak 
shoulder-induced m /z  shift (that reverted to original values in 
analyses of the ensuing freeze/thaw cycles of the same samples). 
These data sets have been omitted from Figure 2. In larger sample 
sets in clinical proteomics, this type of confounder would be 
expected to be equalized by the other samples in the sample set. 
However, rigorous standardization and reproducibility with respect 
to crystallization conditions are underscored by these observa­
tions.
Spiked Samples. In the freeze/thaw and blood clotting 
experiments, we observed that small changes in sample handling 
and data acquisition heavily influenced the quality of the mass 
spectra. In an effort to devise sample handling and sample storage 
guidelines as well as optimal data handling procedures, we 
designed an artificial sample set of spiked and nonspiked serum 
and plasma samples from eight volunteers. The experimental 
approach is outlined in Figure 3 and is based on different storage 
conditions of paired samples that are nonspiked or peptide-spiked 
after initial preparation of serum from blood left to clot for 2 h at 
room temperature. A total of 24 mass spectra of each individual 
serum sample pair, i.e., a total of 192 mass spectra, were acquired 
in this experiment.
The changes taking place upon storage of sera were readily 
discernible in the mass spectra. Figure 4 exhibits a zoom-overlay
Fractionation and mass spectrometry analyses
F ig u re  3. Design of sample preparation experiment. Samples 
(serum as well as plasma) from each individual were split into two 
equal parts. One part was spiked with a peptide and protein standard 
mixture (see Experimental Procedures); the other was not spiked. 
The spiked and nonspiked tubes were further divided into two parts 
and stored at increasing time intervals (0, 1, 4, 8, 24, and 48 h) at 4 
and 24 °C before fractionation with C8-activated magnetic beads and 
mass spectrometric analyses.
plot of spectra of serum samples from one person as a function 
of incubation time at 4 and 24 °C. It is evident that the storage 
temperature is responsible for the largest changes in the mass 
spectra. The most striking changes are the diminishing amounts 
of species below m /z  = 2000. Despite these changes, many of 
the spiked species were consistently recovered at varying signal 
strengths. Four of the spiked molecules, however, were never 
recovered. This may reflect losses during the sample processing 
procedure (i.e., the added material may not be eluted from the 
reverse-phase beads or be degraded during the sample prepara­
tion). The nonrecovered molecules were as follows: substance P 
(1348.66), ACTH clip 1-17 (2094.46), cytochrome c (6181.05), and 
myoglobin (8476.77).
With respect to plasma, we analyzed a number of paired serum 
and plasma samples and found that the two types of material 
required different sample treatment procedures, and thus, sub­
stitution of serum for plasma in future trials may not be recom­
mended without optimizing sample preparation. The effect was 
not due to EDTA, and high-speed centrifugation did not change
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F ig u re  4 . 3D overlay (zoom) plot of mass spectra of a serum sample from one person. Spectra of samples incubated at 0, 1, 4, 8, 24, and 
48 h are shown grouped according to the serum incubation temperature at 4 and 24 °C, respectively. The major changes in serum are seen in 
the low m/z region (900-2000 Da.).
F ig u re  5. Comparison of MS analysis of serum and plasma samples. Two samples from same individual (serum, upper trace; plasma, lower 
trace) were processed for MS using three times the serum volumes for the plasma analysis. Samples were analyzed directly after thawing from 
storage at -2 0  °C.
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F igu re  6. Misclassifications by ClinProTools of sample spectra from 
sera stored at the indicated time and temperature. Samples from 
both 4 and 24 °C, stored in the time interval 0 -1  h are used for 
model building. Dark gray (4 °C) and light gray (24 °C) sample 
data are shown. Sixteen samples are in each time group, which 
gives values of up to 33% misclassification for samples stored at 24 
and 48 h.
the quality of the spectra. Only after using three times the volume 
optimal for serum processing, did plasma samples under otherwise 
identical handling and analysis conditions yield spectra of the 
comparable quality (Figure 5). This may reflect protein degrada­
tion in plasma samples, but further characterization must be 
carried out to address this issue.
To specify a set of minimum requirements for handling of sera 
for clinical proteome analyses, we subsequently used three 
different biostatistical approaches for grouping the artificially 
created binary sample sets. The aim was to assess the influence 
of temperature and incubation time on the predictive performance 
of the classification models without and with (potential) biomarker 
detection. Thus, this part of the study concerns class prediction 
while the above stability studies represent class comparison 
issues.28 Of the 96 potential m/z data sets at each temperature,
F ig u re  7. PCA performance. (A) Scores plot from a linear regression classification model (PLS1) of mass spectra from normal and spiked 
sera. Samples incubated for up to 1 h at 24 °C are included in the model. The sample data divide into two clearly distinguished groups represented 
by spiked (black circles) and nonspiked (blue circles) samples. (B) Deviation of sample prediction. A model created from < 1-h samples incubated 
at 4 and 24 °C. All 0-48-h samples incubated at 4 (light gray) and 24 °C (dark gray) are used to validate the model. From the classification of 
each spectrum, a standard deviation value is given telling how well the each spectrum at a given incubation time is classified. Mean standard 
deviations are depicted as a function of incubation time and temperature. The standard deviation of the validation spectra increases dramatically 
between 1 and 4 h of incubation at 24 °C and after 8 -2 4  h of incubation at 4 °C.
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F ig u re  8 . Modeling performance using sample sets of spiked (S) and nonspiked (N) sera (cf. Figure 3). Results are shown from models based 
on the following: centroid clustering using ClinProTools (upper row), SVM (middle row), and SVM-RFE (lower row). Classification error graphs 
(left panel) show the percentage of correctly classified test samples (i.e., in the subset of samples not used for training) as a function of the 
training sample sets (increasing incubation times at two different temperatures as indicated, numbers of samples in model set and in the test 
set are indicated in parentheses—a total of 96 data set at 4 °C and 94 (2 from the 48-h group did not yield spectra) at 24 °C were used). The 
0 -1 -h  sample sets were not used alone for training in the SVM and SVM-RFE analyses. Graphs in right column shows the outcome (average 
sensitivity (sens) and specificity (spec)) of LOOCV for each of the models based on different modeling sample sets as indicated.
two from the 24 °C group were rejected because their overall peak 
threshold was below that specified by the acquisition settings. 
These two samples belonged to the 48-h storage group.
While the PCA (Unscrambler) and SVM programs include all 
input data points, the ClinProTools software reduces the amount 
of data by peak picking routines. This process reduces data 
complexity from 90 288 data points to 150-200 discrete peaks in 
our spectra. The clustering model approach was used because 
initial comparison indicated that the k-nearest neighbor analyses 
had an overfitting bias (data not shown).28 Each final model relies 
on a reduced number of marker peaks for correct classification 
of unknown sample spectra. We specified a minimum of 5 and a 
maximum of 10 markers for the model building in cluster analyses. 
Since modeling depends on maximizing sample group differences, 
a few of the added markers often sufficed in achieving a complete 
separation of spiked and nonspiked sera. The data show that 
model building is optimal when based on samples treated similarly 
to the test samples. Thus, the fragility of models based on sera 
stored for a short period of time for the predictive analysis of sera
stored for >24 h is even more pronounced when only using the 
data of sera stored at e 1 h (Figure 6). These results indicate that 
long-term (>24 h) storage at any (24 or 4 °C) temperature of test 
samples is harmful for their classification but also that inclusion 
of data sets from samples stored at increasing time and temper­
ature into the model building will yield better classification 
specificity and sensitivity of all the sample sets. This is not 
surprising as the mass spectra from sample data sets with 
increasing incubation time and temperature force the model to 
take into account the decreasing quality of the mass spectra. Since 
the trends in conditions that are interfering with proper model 
building are here obtained with artificially changed sera, it is very 
likely that the suggested detrimental effects of incompatible model 
and test sets in real biological samples will be much more 
pronounced.
When the same sample sets were analyzed with PCA/PLS 
(Unscrambler), spiked sera were discriminated from nonspiked 
sera when a model based on the entire data sets of samples stored 
up to 1 h at both 4 and 24 °C was used (Figure 7A, samples
Analytical Chemistry, Vol. 77, No. 16, August 15, 2005 5121
F ig u re  9 . Frequency plots of models selected by SVM. Shown are the m/z values selected by each of the four models. (A) 4 °C; (B) 24 °C. 
Upper traces show an example of a spiked spectrum from each temperature.
incubated at 24 °C are shown). The actual m /z  values are derived 
from loadings plots that show how much each variable (m /z value) 
contributes to the meaningful variation in the data (sample). A 
linear regression model of these data had a high predictive score 
(r > 0.95) and a high cross-validation score (LOOCV, r > 0.93) 
indicating that the model is robust. When using data from sera 
incubated more than 1 h for the model building, the linear
regression model gets increasingly worse in discriminating the 
spiked from the nonspiked serum samples. This tendency is most 
profound for the models based on serum samples stored at 24 
°C. Figure 7B depicts this in plots of the mean mass spectrum 
standard deviation against the serum incubation time at 4 and 24 
°C. Data were calculated by a linear regression model based on 
the cumulated data sets from sera stored up to 1 h at 4 and 24
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°C. For sera stored at 4 °C, the mean mass spectrum deviation 
starts to increase dramatically somewhere between 8 and 24 h of 
incubation whereas the mean mass spectra deviation in serum 
samples stored at 24 °C has a similar increase already between 1 
and 4 h. Overall, the PCA/PLS analyses again stress the need for 
treating all samples in the same way to get a meaningful basis 
for developing models.
Data were further analyzed using SVM and SVM-RFE. Models 
were generated using four training data sets of increasing size 
and wider range of incubation time values and tested on the 
remaining data. Figure 8 summarizes the results of the SVM and 
SVM-RFE as well as the clustering modeling mentioned above 
together with predictive classifications of test sample sets. Model 
stability was assessed by applying LOOCV to each of the three 
training data sets (four in the case of centroid clustering) (Figure 
8, right panel). SVM and SVM-RFE were applied to data sets 
containing 22 572 m /z  values, i.e. the same data sets that were 
subjected to PCA (cf. above), while the cluster analysis as 
mentioned was based on peak picking (150-200 peaks). Results 
of SVM indicate a better performance when data at 4 °C are used 
instead of 24 °C. Not only does the SVM analysis become more 
stable with respect to small changes of the training set (LOOCV 
accuracy equal to 1), but its performance on the test set also 
improves, with two spiked misclassified spectra, both from the 
group of long incubation time (48 h) compared with six to seven 
misclassifications in the 24 °C group (all 48 h).
This difference in performance does not occur when recursive 
feature elimination is used (Figure 8, lower panel). However, the 
performance of SVM-RFE (average accuracy 0.97-1) is slightly 
worse than that of SVM (average accuracy 1), indicating that little 
information relevant for SVM classification is discarded when 
selecting only 10 out of 22 572 m /z  values. Figure 9 shows 
frequency plots of m /z  values selected by SVM at 4 (Figure 9A) 
and 24 °C (Figure 9B) in the four successive models generated 
from the accumulated data of the four time ranges as indicated. 
Observe that no m /z  value higher than 4500 is selected in any of 
the LOOCV runs. At each of the LOOCV runs, most of the 10 
selected m /z  values were concentrated in the neighborhood of 
one or two true spikes, most of them near spikes of m /z  values 
of 1620 (bombesin, m /z  = 1620.88) and 2465 (ACTH clip 18-39, 
m /z  = 2466.73). Thus, as observed in the other modeling 
approaches as well, one or two of the spikes yield m /z  values of 
enough discriminatory power for optimal classification despite the 
presence of additional markers.
The SVM-based analyses, in agreement with PCA and the 
cluster analyses, support the importance of using model building 
samples and test samples that are treated similarly to avoid
classification problems. SVM offers 10% improvement in accuracy 
on the test set over the cluster analyses while LOOCV does not 
readily support the choice of one computational approach over 
the other. It is important to note that modeling for discriminatory 
analysis does not yield a description of all the significantly changed 
analytes but stops at the number of analytes that attain maximum 
class prediction capabilities, i.e., is different from class comparison 
analyses. In real cases, the trends in the LOOCV specificity and 
sensitivity and in the accuracy error variations observed here with 
artificially enhanced differences between samples must be ex­
pected to be much more significant.
CONCLUSIONS
In the use of mass spectrometric proteome analysis for clinical 
diagnostic purposes, it is mandatory that samples are not 
compromised due to suboptimal handling, transport, and process­
ing. Our results show that clotting time and temperature are 
important factors for serum quality and hence for model building, 
which is compromised in all the computational approaches tested 
here if blood is left to clot at room temperature for more than 3 
h or more than 24 h at 4 °C. Likewise, storage of sera is 
detrimental if exceeding 4 h at room temperature or more than 
24 h at 4 °C. There are no indications in the relatively short time 
span (7-14 days) of these experiments that it is advantageous to 
store samples at -80 °C rather than at -20 °C. Additionally, our 
findings suggest that thaw/freeze cycles have no or very little 
effect on the stability of serum and hence on model building and 
biomarker findings. Using plasma samples, our preliminary results 
indicate that more material must be applied for the sample 
extraction to yield measurable data. Whether this is due to 
changes in proteolysis in plasma as compared to serum remains 
to be established. If archival samples are used for development 
of MS-based proteomic diagnostics, our study emphasizes the 
need for similar treatment of all samples. Finally, the purpose of 
specific studies should be clear before embarking on data analysis;
i.e., the analyses presented here aim at modeling the most efficient 
discrimination between two groups (supervised) and do not aim 
to characterize all significant differences as would be the case in 
class comparison studies.
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